Radius Health, Inc.

Ipsen Pharma S.a.s.

University of Pennsylvania

Wyeth

C Richard Lyttle

Bart Henderson

Nathalie Mondoly

Michael J Dey

Benedicte Rigaud

Michael Sotirios Malamas

Michael David Collini

Robert E McDevitt

James C Keith, Jr

Iwan Suwandi Gunawan

Heather Anne Harris

Eric Steven Manas

Gary Hattersley

Leo M Albert

Jonathan Guerriero

Louis O'Dea

Zhengxin Dong

Dong Zhengxin

The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.

Method of treating osteoporosis comprising administration of PTHrP analog

This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.

Therapeutic regimens

The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.

Treatment of vasomotor symptoms with selective estrogen receptor modulators

Method of drug delivery for bone anabolic protein

The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.

Stable composition comprising a PTHrP analogue

This invention provides estrogen receptor modulators of formula I, having the structure whereinR, R, R, R, R, and R, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Substituted benzoxazoles as estrogenic agents

A composition comprising a soluble peptide of about 23 kD to about 29 kD, capable of causing neutrophil and macrophage chemotaxis, and which is substantially similar to chemotactic factor from peritoneal fluid of mammals with minimal or moderate endometriosis.

Antibody specific for an isolated chemotactic factor from patients with

Isolated chemotactic factor from patients with endometriosis

Growing community of inventors

Bala Cynwyd, PA, United States of America

C Richard Lyttle